Login

Company Executives

Management Team

From Forms 3, 4 and 5 filed in the last 18 months
Officer 2024 pay Source
Kate Haviland
Chief Executive Officer
Title from the Form 4 dated Jul 17, 2025
Not reported
Michael Landsittel
Chief Financial Officer
Title from the Form 4 dated Jul 17, 2025
$4,191,251
Christina Rossi
Chief Operating Officer
Title from the Form 4 dated Jul 17, 2025
$6,542,019
Philina Lee
Chief Commercial Officer
Title from the Form 4 dated Jul 17, 2025
Not reported
Debra Durso-Bumpus
Chief People Officer
Title from the Form 4 dated Jul 17, 2025
Not reported
Tracey L McCain
EVP & Chief Legal Officer
Title from the Form 4 dated Jul 17, 2025
Not reported
Percy H. Carter
Chief Scientific Officer
Title from the Form 4 dated Jul 17, 2025
$5,132,463
L. Becker Hewes
Chief Medical Officer
Title from the Form 4 dated Jul 17, 2025
Not reported
Fouad Namouni
PRESIDENT, R & D
Title from the Form 4 dated Jul 17, 2025
$5,497,313
Ariel Hurley
Principal Accounting Officer
Title from the Form 4 dated Jul 17, 2025
Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 24, 2025 · updated by the 8-K of Jul 18, 2025

Directors
2
serving now
Average tenure
14.0 years
from year joined
Director Age On board Source
Michael J. Tolpa Joined Jul 18, 2025
- -
Nicholas Lydon Leaving at the meeting
68 2011
14 years

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

1 disclosed in the proxy filed Apr 24, 2025
Alexis Borisy, Nicholas Lydon and George Demetri
then-current members of our board of directors who were also founders of IDRx
$78.7 million
August 1, 2022

License of the company's internally discovered KIT exon 13 inhibitor to IDRx in exchange for IDRx Series A preferred stock, with anti-dilution rights, milestones and royalties; the company later received its IDRx shares for $78.7 million when the transaction closed with GSK plc in February 2025.

With IDRx, Inc. Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support